Integration is an obligatory step in the replication of retroviruses (including human immunodeficiency virus type 1 [HIV-1]), in which a linear double-stranded DNA copy of the viral genome is inserted into the chromosomal DNA of the host cell (4, 26, 51) . It is generally believed that integration is required for the efficient transcription of viral DNA. Although limited viral gene expression was reported for some HIV-1 integrase (IN)-deficient mutants (44) , integration appears to be required for the production of viral particles and for the establishment of a productive HIV-1 infection in human T-cell lines, cultured primary peripheral blood lymphocytes, and macrophages (20, 33, 53) .
Integration is mediated by IN, a virus-encoded, virion-associated protein. IN is derived from the C terminus of the GagPol polyprotein by proteolytic cleavage. Initially, it was believed that the only function of IN was to mediate the integration of viral DNA; however, the structure of viral particles produced by some IN-defective HIV-1 mutants is aberrant, which suggests that IN could play a role in virion assembly and maturation (20, 41) .
The enzymatic activities of retroviral IN have been extensively studied in vitro. Reactions of this type can be performed either with preintegration complexes obtained from infected cells or by with purified recombinant IN and synthetic oligonucleotides that mimic the ends of viral DNA, which are the natural substrates for IN (5, 8, 10, 13, 16, 19, 22, 24, 25, 30-32, 40, 49) . IN is an endonuclease that removes two nucleotides from the 3Ј ends of linear viral DNA (4, 26, 51) . This reaction creates recessed 3Ј ends, which subsequently participate in a concerted strand transfer reaction that joins the 3Ј termini of viral DNA to the 5Ј ends of chromosomal DNA (4, 26, 51) . In vivo, both ends of viral DNA are joined to the chromosomal DNA of the host cell. The distance between the sites where viral ends are inserted into the host genome is characteristic of the strain of retrovirus and varies between 4 and 7 bases (4, 26, 51) . The IN-mediated joining reaction leaves small gaps at the host DNA-viral DNA junction that are repaired, presumably by host cell enzymes. In vitro, IN can catalyze the reverse reaction, disintegration, in which the product of the integration reaction is cleaved to produce the initial substrates of the strand transfer reaction (11) . Integration is both specific (involving U3 and U5 terminal sequences of the viral long terminal repeats) and nonspecific (binding to a target DNA). All of the enzymatic activities require the presence of a divalent metal ion.
There appear to be three relatively independent domains in HIV-1 IN (9, 18) . The N-terminal domain contains a zinc finger-like motif, HHCC (H-X 3-7 -H-X 23-32 -C-X 2 -C) (7, 9, 29) , which binds a metal ion and may be involved in the specific recognition of viral DNA ends. Mutations that alter the conservative Cys and His residues in this domain eliminate 3Ј processing and strand transfer activities and reduce but do not eliminate disintegration activity. The central domain, which is relatively resistant to proteases, contains the highly conserved D,D 35 -E region (D-X 39-58 -D-X 35 -E) (18, 19, 48) , which forms the active site for all of the enzymatic activities of the protein.
Relatively little is known about the functions of a C-terminal domain, which is less well conserved, varying in both length and sequence. However, this domain is important, since the deletion of the C terminus impairs IN functions (14, 18, 19) . This segment appears to play a role in binding DNA (21, 35, 45, 54) .
Crystal structures of the catalytic cores of HIV-1 (15) and Rous sarcoma virus (6) INs and a nuclear magnetic resonance spectroscopy-based structure of the C-terminal domain (34) have recently been reported. However, the structure of the complete molecule is not yet known. We have probed the functions of wild-type IN protein with monoclonal antibodies (MAbs) and Fab fragments derived from these MAbs. Here, we report the characterization and molecular cloning of a monoclonal antibody Fab fragment which binds to an epitope on the C terminus of HIV- 1 Construction of plasmids. Plasmids were constructed by standard methods (39) .
(i) IN expression plasmid. E. coli DH5␣ cells were used to construct and maintain the IN expression plasmid. The HIV-1 IN coding sequence was PCR amplified from a plasmid that contained the BH10 provirus (55) with the forward primer spanning the first IN codon (AAAACATATGTTTTTAGATGGAATA GATAAGGCCCA) and the reverse primer spanning the termination codon of the pol gene (AAAAGGATCCCTTTTCCATGTTCTAATCCTCATCC). NdeI and BamHI recognition sites were introduced into the 5Ј ends of the forward and reverse primer, respectively. The PCR fragment was cloned as a NdeI-BamHI insert into the vector pET15b (Novagen), creating plasmid pIN10, so that the N-terminal coding sequence of IN was fused to a 6ϫHis sequence encoded by the vector.
(ii)Fab 35 expression plasmid. Sequences encoding the Fd fragment of the heavy and light chains of MAb 35 were cloned from hybridoma 35 cells by phage display (12, 52) . Poly(A) ϩ RNA was isolated from the hybridoma cells with the Micro-FastTrack mRNA isolation kit (Invitrogen). cDNAs corresponding to the Fd fragment of the heavy chain and the entire light () chain were synthesized and amplified as follows. A 1-g portion of the poly(A)
ϩ RNA was annealed with 1 g of the oligo(dT) 18 primer, and the first DNA strand was synthesized with avian myeloblastosis virus reverse transcriptase (Boehringer Mannheim) at 42ЊC for 1 h. cDNAs for the Fd and fragments were then amplified with Taq polymerase (Perkin-Elmer Cetus) in two separate PCRs with the sets of oligonucleotide primers described previously (37) . The forward primers correspond to sequences encoding the N-terminal segments of the heavy-and light-chain variable regions. The reverse primers for the Fd fragment were complementary to the CH1 and hinge junction regions of the ␥1, ␥2A, and ␥2B H-chain isotypes, and the reverse primers for the fragment were complementary to the C terminus of the L()-chain constant region. PCR products were gel purified and extended by jumping PCR (37) followed by PCR assembly of a Fab expression cassette encoding both Fd and chains. The fragment was cleaved with restriction endonucleases SfiI and NotI and ligated to the phage display vector pFAB5c (37) (kindly provided by J. Engberg). Electroporation-competent E. coli XL1-Blue cells (Stratagene) were electroporated with the ligated DNA and plated on 2ϫYT agar (39) containing 2% glucose and ampicillin (100 g/ml), yielding a library of Fab fragments containing 5 ϫ 10 6 clones. To generate phage particles displaying the Fab fragment, clones of the transformed cells were superinfected with a helper phage, VCSM13 (Stratagene), and grown overnight. Phage particle minipreps were prepared from culture supernatants by two rounds of polyethylene glycol precipitation followed by acetic acid precipitation as described previously (43) . To select phage clones that displayed the functional Fab fragment, phage minipreps were tested for the ability to bind IN by enzyme-linked immunosorbent assay (ELISA). Wells of 96-well plates (Costar) were coated overnight at 4ЊC with IN diluted in phosphate-buffered saline (PBS; 20 g/ml) and then blocked with 3% bovine serum albumin (BSA) in PBS. The wells were washed with PBS that contained 0.1% Tween 20 and filled with phage minipreps that were diluted twofold with PBS-3% BSA. Following incubation at room temperature for 2 h, the wells were washed, incubated with biotinylated sheep anti-M13 antibodies (5Ј-3Ј, Inc.), washed, and incubated with streptavidin conjugated with horseradish peroxidase (GIBCO BRL). Finally, the wells were washed, and the immune complexes were detected with p-nitrophenylphosphate (pNPP) (Kirkegaard & Perry).
To construct a plasmid expressing a soluble Fab 35 fragment, DNA from the IN-binding phagemid clone was cleaved with restriction endonuclease EagI (this cleavage released a fragment containing a truncated gene III) (37) and the fragment containing the vector and Fab coding sequences was gel purified and recircularized by ligation. The resulting plasmid was designated pFAB35(8)s. In this plasmid, the C-terminal coding region of the L() chain was fused to the 6ϫHis sequence encoded by the vector. IN protein carrying the N-terminal 6ϫHis affinity tag was purified from induced BL21(DE3)pLysS/pIN10 cells as described previously (19, 40, 46) with modifications. The cells were resuspended in buffer A (20 mM N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid [HEPES; pH 7.5], 5 mM dithiothreitol, 1 mM EDTA, 0.5 mg of lysozyme per ml) and sonicated. The homogenate was subjected to centrifugation at 10,000 ϫ g for 30 min, and the pellet was resuspended in buffer B (20 mM HEPES [pH 7.5], 100 mM NaCl, 1 mM ␤-mercaptoethanol). The suspension was incubated on ice for 15 min and subjected to centrifugation at 10,000 ϫ g for 30 min. The pellet was resuspended in buffer C (20 mM HEPES [pH 7.5], 1 M NaCl, 1 mM ␤-mercaptoethanol, 10 mM 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate [CHAPS] ) and stirred at 4ЊC for 2 h. The sample was subjected to centrifugation at 85,000 ϫ g for 1 h. The supernatant was loaded onto a Ni 2ϩ nitrilotriacetic acid column (Qiagen) equilibrated with the buffer C. The column was washed with buffer C and then with buffer D (50 mM sodium phosphate [pH 6 .0], 300 mM NaCl, 1 mM ␤-mercaptoethanol, 10 mM CHAPS). IN was eluted with a 0 to 500 mM imidazole gradient in buffer D. Peak fractions were pooled, yielding a protein preparation that was approximately 90% pure.
Pooled fractions from the Ni 2ϩ NTA column were loaded onto a Sephacryl S-200 column (Pharmacia) equilibrated with 20 mM HEPES (pH 7.5)-1 M NaCl-1 mM EDTA-10 mM CHAPS. Fractions containing the majority of IN were pooled, diluted fivefold with buffer E (20 mM HEPES [pH 7.5], 1 mM EDTA, 10 mM CHAPS), and loaded onto a heparin-Sepharose column (Pharmacia, NJ) equilibrated with Buffer E containing 180 mM NaCl. The column was washed with equilibration buffer, and the IN was eluted by applying a 180 to 800 mM NaCl gradient in buffer E. Fractions containing IN were pooled, aliquoted, and stored frozen at Ϫ70ЊC. The final concentration of NaCl in the purified IN preparation was 570 mM. The purity of IN eluted from the heparin-Sepharose column approached 100%.
(ii) Soluble Fab 35. Plasmid pFAB35(8)s was introduced into E. coli XL-1Blue cells, and the expression of soluble Fab 35 was induced by adding IPTG. The Fab 35 fragment was purified from the periplasmic fraction of the induced XL-1Blue/ pFAB35(8)s cells by immobilized-metal affinity chromatography (23, 28, 42) followed by ion-exchange chromatography. The periplasmic extract was obtained by mild osmotic shock (38) . Briefly, cells were resuspended in 0.5 M sucrose-20 mM Tris (pH 8.0)-1 mM EDTA. An equal volume of the same buffer diluted fivefold with water was added, and the suspension was stirred at 4ЊC for 1 h. The suspension was subjected to centrifugation at 10,000 ϫ g for 20 min, and the supernatant was dialyzed against loading buffer (0.5 M betaine-glycine, 40 mM sodium phosphate [pH 7.5]). The supernatant was subjected to centrifugation at 85,000 ϫ g for 1 h and loaded onto a metal chelate Fast Flow Sepharose column (Pharmacia) that was charged with Zn 2ϩ and equilibrated with loading buffer. The column was washed with loading buffer, and the Fab 35 was eluted with a 0 to 500 mM imidazole gradient in loading buffer. IN enzymatic activity assays. All enzymatic assays were performed essentially as described previously (19) with minor modifications. To prepare a substrate for the 3Ј-end processing reaction, oligonucleotides AE117 and AE150 (19) , whose sequences correspond to the terminal sequence from the U5 end of the HIV-1 long terminal repeat, were annealed, filled in with [␣-32 P]TTP with Sequenase version 2.0 DNA polymerase (U.S. Biochemical Corp.) and separated from unincorporated nucleotides by quick-spin column chromatography on Sephadex G-25. The substrate for the strand transfer reaction was formed by annealing an unlabeled oligonucleotide AE117 with AE119 which was 5Ј-end labeled with T4 polynucleotide kinase. The substrate for the disintegration assay was prepared by self-annealing the 5Ј-end-labeled "dumbbell" oligonucleotide (11) . Enzymatic assays were performed with 0.45 g (13.5 pmol) of purified IN (1 l of the IN preparation) and 1 pmol of the oligonucleotide substrate (specific activity, 1.23 ϫ 10 6 cpm/pmol) in reaction buffer (20 mM HEPES [pH 7.5], 10 mM MnCl 2 , 1 mM dithiothreitol, 0.05% Nonidet P-40) in a total volume of 20 l. Reaction mixtures were incubated at 37ЊC for 1 h, and the reaction was stopped by adding an equal volume of 2ϫ loading buffer (80% formamide, 0.01% bromphenol blue, 0.01% xylene cyanol). The mixtures were heated at 96ЊC and run on a 20% polyacrylamide-7 M urea gel in Tris-borate-EDTA (TBE) buffer. IN reaction products were detected by autoradiography of the wet gels at Ϫ70ЊC.
IN DNA-binding activity assay. UV cross-linking was used to determine DNAbinding activity in the presence of Fabs. The reaction volume was 20 l. IN and the Fab were mixed in microcentrifuge tubes under reaction conditions identical to those used for the enzymatic assays and incubated on ice for 20 min. The oligonucleotide used as the disintegration substrate was added, and the mixtures were incubated on ice for 15 min. Following a 15-min incubation at room temperature, the mixtures were irradiated with 280 nm UV light, using a Transilluminator (Fotodyne). After an 8-min exposure at room temperature, an equal volume of 2ϫ protein sample buffer was added to the mixtures. The reaction mixtures were heated at 100ЊC for 4 min and fractionated by SDS-PAGE (12% polyacrylamide). Cross-linked DNA-IN complexes were detected by autoradiography of the dried gels at Ϫ70ЊC.
Preparation of the purified MAbs, Fab, and F(ab) 2 fragments. (i) MAb purification. Ascitic fluid was delipidated by centrifugation at 6,000 ϫ g for 15 min and diluted fivefold with buffer A (1.5 M glycine, 3 M NaCl [pH 8.9]). The MAbs were bound to a protein A-Sepharose 4 Fast Flow column (Pharmacia), and the column was washed with buffer A. The MAbs were eluted with 100 mM citric acid (pH 3.0) and neutralized with 1 M Tris-Cl (pH 8.0). The buffer was exchanged with 50 mM sodium acetate (pH 5.5), and then the MAb was concentrated with a stirred-cell concentrator with a YM 30,000-molecular-weightcutoff cellulose acetate membrane (Amicon). Purified MAbs were aliquoted and stored at Ϫ80ЊC.
(ii) Fab fragment preparation. Purified MAbs were diluted to a concentration of 2 mg/ml with 50 mM sodium acetate (pH 5.5). Papain conjugated to agarose beads (Sigma) was added at 0.313 mg/mg of MAb in the presence of 50 mM cysteine and 1 mM EDTA. The reaction mixture was incubated at 37ЊC for 6 to 8 h in a shaking water bath. The beads containing the bound papain were removed by filtration through a 0.2-m-pore-size cellulose acetate membrane (Millipore). The reaction mixture was diluted twofold with 1.5 M glycine-3 M NaCl (pH 8.9), and Fab fragments were separated from Fc fragments by binding the Fc fragments to a protein A-Sepharose 4 Fast Flow column. The flowthrough material was collected, and the buffer was exchanged with 50 mM sodium phosphate-100 mM NaCl (pH 6.0) with a Centricon-30 concentrator (Amicon).
(iii) F(ab) 2 preparation. The buffer containing the MAbs was exchanged with 100 mM citric acid (pH 3.0), and the MAbs were diluted to 2 mg/ml. Pepsin conjugated to agarose beads (Sigma) was added at 0.1 mg/mg of MAb. The reaction was allowed to proceed for 1.5 h at 37ЊC in a shaking water bath and was terminated by removing the beads containing the bound pepsin by filtration through a 0.2-m cellulose acetate membrane. The buffer was exchanged with 50 mM sodium phosphate-100 mM NaCl (pH 6.0) with a Centricon-30 concentrator.
IN assays in the presence of MAbs and their fragments. All MAbs and their fragments were added to the reaction mixtures as follows, unless specified otherwise. MAbs and F(abЈ) 2 fragments were added at a MAb/IN molar ratio of 1:1. The Fab fragments were added at a Fab/IN ratio of 2:1. Anti-mouse and antirabbit IgGs were added at an IgG/Fab/IN ratio of 1:2:1 (or an IgG/IN ratio of 1:1 for control experiments). The reaction mixtures were prepared without the labeled oligonucleotide substrates and preincubated on ice for 30 min. Labeled substrates were added, and the reactions were then allowed to proceed at 37ЊC for 1 h. The reactions were stopped by adding equal volumes of 2ϫ loading buffer, and the mixtures were run on a 20% polyacrylamide-7 M urea gel in TBE buffer as described above.
Epitope mapping. The IN epitope recognized by MAb 35 was determined with the NovaTope Epitope-Mapping System (Novagen). A DNA fragment containing the IN coding sequence was obtained by cleavage of pIN10 by restriction endonucleases NdeI and BamHI. A mixture of short random DNA fragments (ϳ120 bp long) was generated by digestion of the IN DNA fragment with DNase I. The peptide library was constructed by cloning these fragments into the pTOPE-1b(ϩ) vector as recommended by the manufacturer. Expression of the gene 10-IN peptide fusion proteins was induced by transferring the library onto the nitrocellulose filters impregnated with IPTG. Filter replicas were incubated on NZY agar plates (39) at 37ЊC, and colonies were lysed and then probed with MAb 35. Positive clones were identified by incubating the filters with alkaline phosphatase-conjugated goat anti-mouse IgG and then with nitroblue tetrazolium chloride and 5-bromo-4-chloro-3-indolylphosphate (GIBCO BRL). Plasmid DNA was isolated from positive clones, and the sequence of the IN-derived inserts was determined by dideoxy termination sequencing with Sequenase version 2.0 DNA polymerase. The specificity of MAb 35 for the IN-derived peptides was confirmed by immunoblot analysis of the fusion proteins synthesized by the positive clones.
RESULTS
Fab fragments inhibit HIV-1 IN, the corresponding MAbs do not. We used oligonucleotide-based enzymatic assays to test a panel of five MAbs (clones 3, 4, 17, 35, and 44) specific for HIV-1 IN for the ability to inhibit IN. These antibodies were obtained from hybridomas generated following immunization of mice with a fragment of a recombinant HIV-1 IN protein (27) . The antibodies recognized the C terminus of HIV-1 IN (data not shown). All antibodies were isolated from ascitic fluid by purification on a protein A-Separose column. In preliminary experiments, the antibodies were shown to bind the IN protein under the conditions of an enzymatic assay (in a buffer of low ionic strength) (data not shown). Purified antibodies were added to the strand transfer and disintegration reactions at an antibody/IN molar ratio of 1:1, and none of the MAbs inhibited these enzymatic activities. In fact, some of the MAbs consistently enhanced strand transfer activity when they were added at a molar excess over IN (data not shown). Fab fragments were prepared from the antibodies by papain cleavage. The Fc fragments were removed by chromatography on protein A-Sepharose. The MAbs and their Fab fragments were tested in parallel in strand transfer and disintegration reactions. MAbs were added to IN at a molar ratio of 1:1 (a ratio of antigen-binding sites to IN of 2:1). Fabs were added at twice this ratio (taking into account the difference in the number of an antigen-binding sites on MAbs and Fabs). The mixtures were incubated on ice for 30 min to allow the antibodies to bind IN. Oligonucleotide substrates were then added, and the reactions were allowed to proceed at 37ЊC. As shown in Fig. 1 , neither the strand transfer nor the disintegration was inhibited by any of the MAbs (compare lanes 3, 5, 7, 9, and 11 with lanes 2). In contrast, Fab fragments of the antibodies completely abolished the strand transfer activity (Fig. 1A, compare (Fig. 2, lane 4) .
We then tested the panel of the Fabs in the 3Ј-end-processing assay, in which IN cleaves a dinucleotide (GpT) from a double-stranded oligonucleotide that mimics the U5 end of viral DNA. Fab fragments were preincubated with the enzyme on ice at a Fab/IN ratio of 2:1, the oligonucleotide substrate was added, and the reaction mixtures were incubated at 37ЊC. All of the Fabs dramatically inhibited the 3Ј-end-processing reaction (Fig. 3) . None of the parental MAbs inhibited 3Ј-end processing (data not shown).
Thus, Fab fragments of several MAbs that recognize the C terminus of IN were able to differentially inhibit the enzymatic activities of HIV-1 IN. The inhibitory effects of the Fab fragments on the enzymatic activities of HIV-1 IN are summarized in Table 1 .
Fab fragments do not impair the DNA-binding activity of the HIV-1 IN. Binding of viral DNA and host chromosomal DNA are critical steps in the IN-catalyzed reactions. The Cterminal domain of the HIV-1 IN is believed to contain a region that is involved in DNA binding (21, 32, 45, 54) . It was possible that binding the Fab fragment to the C terminus of the IN would impair the ability of IN to bind DNA. Fab fragments were preincubated with IN, and a 32 P-labeled disintegration substrate was then added to the reaction mixture. The mixtures were incubated to allow DNA binding, the DNA-IN complexes were cross-linked by UV light, and the reaction mixture was fractionated by SDS-PAGE (Fig. 4) . A major cross-linked product was detected as a band of about 45 kDa, which corresponded to the expected molecular mass of the IN monomer (33 kDa) cross-linked to the 38-mer oligonucleotide substrate (12.3 kDa). Higher-molecular-mass complexes (ϳ90 kDa) could represent IN dimers complexed to one or two substrate molecules. As can be seen in Fig. 4 In the UV cross-linking assay (Fig. 4) , Fab fragments were present in twofold molar excess relative to IN. To ensure that the DNA was bound to an IN-Fab complex rather than to free IN, we performed a titration experiment in which Fab 35 was incubated with IN at increasing Fab 35/IN molar ratios, radiolabeled disintegration substrate was added, and the mixture was incubated to allow DNA binding. The reaction mixtures were then irradiated with UV light and the cross-linking products were resolved by SDS-PAGE as described above. Aliquots of the same reaction mixtures were incubated at 37ЊC to measure the disintegration activity. IN retained the ability to bind DNA even in the presence of a 10-fold molar excess of Fab 35, whereas the disintegration activity was completely inhibited (data not shown). Furthermore, by using anti-mouse IgG, we were able to immunoprecipitate DNA that was cross-linked to IN in the presence of incubated to allow the enzyme-Fab interaction. Finally, the DNA substrates were added, and the reactions were allowed to proceed under standard conditions. As can be seen in 7) nor the disintegration activity (data not shown). The effect of adding peptide SP-805 to a strand transfer assay mixture was repeated with peptide/Fab molar ratios ranging from 0.2:1 to 2:1. No strand transfer activity was detected at molar ratios of 0.2:1 to 0.5:1, and only trace activity was observed at ratios of 0.6:1 to 0.9:1. A sharp increase in the strand transfer activity was observed at a ratio of 1:1 (data not shown). No rescue was observed in the presence of the nonspecific control competitor peptide SP-718 at the same concentration. On the other hand, the Fab 35-specific peptide SP-805 failed to rescue strand transfer activity inhibited by Fabs 3 and 4 at peptide concentrations that were sufficient to rescue Fab 35-inhibited strand transfer reaction (data not shown).
Titration of the specific competitor peptide SP-805 in the 3Ј-end-processing assay showed that this activity could be rescued by a substantially lower concentration of the competitor peptide than could strand transfer activity (data not shown). As in the case of the strand transfer experiment, no rescue by the nonspecific control peptide SP-718 was observed. The Fab 35-specific peptide SP-805 did not relieve the inhibition of 3Ј-end processing caused by Fabs 3 and 4.
We tested the effect of the SP-805 and SP-718 peptides in the absence of Fab 35 on the IN-catalyzed strand transfer and disintegration reactions. IN was mixed with the peptides at peptide/IN molar ratios of 6:1, 3:1, and 0.5:1. Neither the strand transfer nor the disintegration reaction was affected by the inclusion of either specific or nonspecific peptides, even in the presence of molar excess of each of the peptides (data not shown), indicating that the rescue of Fab 35-inhibited reactions was a result of specific Fab 35-peptide interaction.
The minimal IN concentration required for strand transfer is different from the amount required for 3-end processing and disintegration. The peptide titration data suggest that the minimal concentration of enzyme needed for the strand transfer, 3Ј-end-processing, and disintegration reactions are different. To test this conjecture, we performed 3Ј-end-processing, strand transfer, and disintegration reactions with serial twofold dilutions of IN in the absence of Fab. At IN concentrations of 1.36 and 0.68 M, all three activities were observed (Fig. 6,  compare lanes 2 and 3 with lanes 1) . However, further dilution of the enzyme to 0.34 M completely abolished the strand transfer activity whereas 3Ј-end-processing and disintegration activities declined in a concentration-dependent manner but were still detectable at IN concentrations as low as 0.0425 M (lanes 4 to 7) . 
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A similar experiment was performed by Engelman and Craigie (19) , who obtained slightly different results. They reported that disintegration activity was quite stable even at low enzyme concentrations; however, in their experiments, the joining reaction and 3Ј-end processing responded relatively similarly to enzyme dilution. There are modest differences in the protocols; however, we cannot account in any simple way for the differences between their results and ours.
The ability to inhibit IN activity depends on the antibody valence. As can be seen from Fig. 1 , intact MAbs possessing two antigen-binding sites did not inhibit IN whereas monovalent Fab fragments generated from the same antibodies were strong inhibitors. This suggests that the ability of the antibody-IN interaction to affect IN activities might be dependent on the number of antigen-binding sites on the antibody (or the antibody fragment). To test this hypothesis, a secondary antimouse antibody was added to the inhibitory Fab fragment to bring two Fab fragments together, recreating a bivalent complex. A purified polyclonal rabbit anti-mouse IgG was added to Fab 35, the resulting complex was mixed with IN, and then the DNA substrate was added. As shown in Fig. 7 , the presence of the anti-mouse IgG completely restored both the strand transfer (Fig. 7A , compare lane 5 with lane 4) and disintegration (Fig. 7C , compare lane 5 with lane 4) activities inhibited by Fab 35. The effect of the anti-mouse IgG was concentration dependent; it decreased with the decrease of the anti-mouse IgG/Fab 35 molar ratio (Fig. 7A and C, lanes 5 to 10) . As expected, no rescue of the enzyme activities was observed upon addition of goat anti-rabbit IgG, which is unable to bind mouse Fab fragments (compare Fig. 7B, lane 1, with Fig. 7A, lane 5, and Fig.  8B, lanes 6 and 7) . Neither anti-mouse nor anti-rabbit IgG affected the activity of IN (compare Fig. 7B, lanes 2 and 3, with Although F(abЈ) 2 derivatives of the Igs lack the Fc portion of the molecule, the two Fab fragments are connected by a disulfide bridge. If it is the monovalent and bivalent nature of the Fabs and their corresponding MAbs that distinguishes their ability (or inability) to inhibit IN, F(abЈ) 2 35 should not be able to inhibit IN-catalyzed reactions. F(abЈ) 2 35 was obtained from MAb 35 by pepsin digestion. It did not inhibit either strand transfer or disintegration, even when added in molar excess over IN (Fig. 8, compare lanes 2, 4, The inhibition of the enzymatic activities of HIV-1 IN by Fab 35 is similar to what has been reported for C-terminal deletion mutants (14) . Deletions ranging in size from 22 to 32 residues have been reported to inhibit strand transfer activity; the effect of such deletions on 3Ј-end processing is more controversial; however, it is possible that the residual cleavage activity claimed in some reports is due to contamination by E. coli exonuclease (14, 18, 19) .
It is clear that the C terminus of HIV-1 IN is important in the viral life cycle. Modifying a molecular clone of HIV-1 to remove 54 amino acids from the C terminus of IN results in the production of a virus that is replication defective; however, this deletion appears to have an effect on virion maturation in addition to whatever effects there are on the enzymatic activity of IN (20) .
It is generally believed that the multimerization of IN subunits is an essential step in the formation of an enzymatically active complex with the DNA substrates. However, the number of IN subunits in the complex remains unknown. The following observations suggest that different enzymatic activities of HIV-1 IN could require different degrees of multimerization. (i) Relative to other enzymatic activities of IN, a significantly higher concentration of Fab 35 was required to completely inhibit disintegration than to abolish strand transfer activity.
(ii) A much lower concentration of a specific competitor peptide was necessary to rescue disintegration reactions inhibited by Fab 35. A concentration of peptide sufficient to rescue the disintegration reaction was able to effect only a partial rescue of the 3Ј-end-processing reaction. However, at this concentration, the strand transfer activity was still completely inhibited. (iii) The effects of varying the IN concentration on the forward (strand transfer) and reverse (disintegration) reactions (in the absence of inhibitory Fab) are different. Since a decrease in the concentration of a multimeric protein can promote the dissociation of a multimer, it seems reasonable to suggest that the binding of Fab 35 to the C terminus of HIV-1 IN lowers the concentration of free enzyme below the level required to form the active oligomer. This concentration of enzyme necessary for the strand transfer activity appears to be different from that needed for the disintegration activity, suggesting that these activities might require different degrees of IN multimerization, a suggestion that has been made by others (19) .
Retrovirus integration could be an attractive target for the development of antiretrovirus therapy. Integration is a critical step in viral replication; in addition, the integration reaction does not appear to have a counterpart in the growth and differentiation of normal cells. We have characterized and cloned a MAb Fab fragment which is able to inhibit 3Ј-endprocessing and strand transfer activities of HIV-1 IN that are known to be essential steps in the in vivo integration process. Recently, a single-chain antibody derived from a human MAb that recognizes the CD4-binding region of HIV-1 envelope protein has been expressed intracellularly in eukaryotic cells (36) . The antibody inhibited processing of the envelope precursor and syncytium formation, and it substantially reduced the infectivity of the HIV-1 particles produced by antibody- 9) . Radioactively labeled disintegration substrate was added, and the reaction mixtures were incubated under standard conditions. Reaction products were resolved by PAGE (20% polyacrylamide) and detected by autoradiography. In lanes 1, the oligonucleotide substrate was incubated in the reaction buffer without any added protein. In lanes 2, the oligonucleotide substrate was incubated with IN in the absence of MAb or Fab.
expressing cells. This, together with the recent demonstration of successful expression and targeting of active antibody fragments to specific subcellular compartments (2, 3, 50) , raises the possibility that the intracellular expression of Fab fragment that interferes with essential viral functions (for example, integration) will provide a basis for the development of an antiretrovirus gene therapy.
